BioSpace News Archive

Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has enrolled the first patient in its Phase III clinical study involving ADL018, the Company’s biosimilar candidate to XOLAIR®.

Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technology, announced that it has completed the acquisition of MedAlliance, a Switzerland-based developer of drug-eluting balloon technology.

Checkpoint Therapeutics, Inc. announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series A warrants to purchase up to an aggregate of 1,734,105 shares of common stock.

California Life Sciences, the state’s life sciences membership organization, announced the finalists for the 2023 Pantheon Awards.

Nerviano Medical Sciences S.r.l., and Nerviano Medical Sciences, Inc. announced today it will present initial data from the PARP1 inhibitor Phase 1 studies at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15 in Boston, MA.

The Feinstein Institutes for Medical Research congratulates two scientists from the University of Pennsylvania Perelman School of Medicine, Katalin Karikó, PhD, and Drew Weissman, MD, PhD, for being awarded the 2023 Nobel Prize in Physiology or Medicine for their groundbreaking messenger RNA research that helped develop mRNA-based coronavirus disease 2019 vaccines.

MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq andConvenes an Extraordinary General Shareholders Meeting

ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO) today announced the hosting of an investor call and webcast on Tuesday, October 3rd at 8:00 AM EDT to share interim Phase 2 ASPEN-06 clinical trial results of evorpacept for the treatment of advanced HER2-positive gastric cancer.

Acutus Medical, Inc. granted equity awards on October 1, 2023 that were approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to 3 individuals hired by Acutus in September 2023.

Cytokinetics, Incorporated, announced upcoming presentations at the 2023 Hypertrophic Cardiomyopathy Medical Society Scientific Sessions on October 6, 2023, and at the Heart Failure Society of America Annual Scientific Meeting, taking place from October 6-9, 2023, both taking place in Cleveland, OH.